Hemarthrosis in a patient on warfarin receiving ceftaroline: A case report and brief review of cephalosporin interactions with warfarin

Annals of Pharmacotherapy

Volumn 46, Issue 7-8, 2012, Pages

  Bohm, Nicole M ^a   Crosby, Brittany ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Bleeding; Ceftaroline; Cephalosporins; Drug interaction; Hemarthrosis; Vitamin K antagonist; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANASTROZOLE; CARVEDILOL; CEFTAROLINE; CEFTRIAXONE; DEXAMETHASONE; MELPHALAN; OMEPRAZOLE; SIMVASTATIN; VANCOMYCIN; WARFARIN;

AGED; ALCOHOL CONSUMPTION; ANTIBIOTIC THERAPY; ARTICLE; BEDTIME DOSAGE; CASE REPORT; CELLULITIS; FEMALE; HEMARTHROSIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; PRIORITY JOURNAL; SHOULDER PAIN;

EID: 84864773110     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q771     Document Type: Article

References (42)

1. Wallin R, Sane DC, Hutson SM. Vitamin K 2,3-epoxide reductase and the vitamin K-dependent gamma-carboxylation system. Thromb Res 2002;108:221-226. doi: 10.1016/S0049-3848(03)00060-4
2. Lee A, Crowther M. Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure. J Thromb Thrombolysis 2011;31:249-258. doi: 10.1007/s11239-011-0555-z
3. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidencebased clinical practice guidelines. 8th ed. Chest 2008;133:160-198. doi: 10.1378/chest.08-0670
4. Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007;41:674-680. doi: 10.1345/aph.1H423
5. Conly J, Stein K. Reduction of vitamin K2 concentrations in human liver associated with the use of broad spectrum antimicrobials. Clin Invest Med 1994;17:531-539.
6. Udall JA. Human sources and absorption of vitamin K in relation to anticoagulation stability. JAMA 1965;194:107-109.
7. Davydov L, Yermolnik M, Cuni LJ. Warfarin and amoxicillin/clavulanate drug interaction. Ann Pharmacother 2003;37:367-370. doi: 10.1345/aph.1C243
8. Zhang Q, Simoneau G, Verstuyft C, et al. Amoxicillin/clavulanic acidwarfarin drug interaction: a randomized controlled trial. Br J Clin Pharmacol 2011;71:232-236. doi: 10.1111/j.1365-2125.2010.03824.x
9. Panagiotidis G, Bäckström T, Asker-Hagelberg C, Jandourek A, Weintraub A, Nord CE. Effect of ceftaroline on normal human intestinal microflora.Antimicrob Agents Chemother 2010;54:1811. doi: 10.1128/AAC.01716-09
10. Saravolatz LD, Stein GE, Johnson LB. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2011;52:1156-1163. doi: 10.1093/cid/cir147
11. Strom BL, Schinnar R, Gibson GA, Brennan PJ, Berlin JA. Risk of bleeding and hypoprothrombinemia associated with NMTT side chain antibiotics: using cefoperazone as a test case. Pharmacoepidemiol Drug Saf 1999;8:81-94.
12. Agnelli G, Favero AD, Parise P, et al. Cephalosporin-induced hypoprothrombinemia: is the N-methylthiotetrazole side chain the culprit? Antimicrob Agents Chemother 1986;29:1108-1109.
13. Welage LS, Borin MT, Wilton JH, et al. Comparative evaluation of the pharmacokinetics of N-methylthiotetrazole following administration of cefoperazone, cefotetan, and cefmetazole. Antimicrob Agents Chemother 1990;34:2369-2374.
14. Kerremans AL, Lipsky JL, Van Loon J, Gallego MO, Weinshilboum RM. Cephalosporin-induced hypoprothrombinemia: possible role for thiol methylation of 1-methyltetrazole-5-thiol and 2-methyl-1,3,4-thiadiazole-5-thiol. J Pharmacol Exp Ther 1985;235:382-388.
15. Package insert. Teflaro (ceftaroline fosamil). St. Louis, MO: Forest Laboratories, Inc., February 2011.
16. Bartlett JG. Antibiotic-associated diarrhea. N Engl J Med 2002;346:334-339.
17. Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998;279:657-662.
18. Smith JK, Aljazairi A, Fuller SH. INR elevation associated with diarrhea in a patient receiving warfarin. Ann Pharmacother 1999;33:301-304. doi: 10.1345/aph.18171
19. Custódio das Dôres SM, Booth SL, Martini LA, et al. Relationship between diet and anticoagulant response to warfarin: a factor analysis. Eur J Nutr 2007;46:147-154. doi: 10.1007/s00394-007-0645-z
20. Couris R, Tataronis G, McCloskey W, et al. Dietary vitamin K variability affects International Normalized Ratio (INR) coagulation indices. Int J Vitam Nutr Res 2006;76:65-74.
21. Lurie Y, Loebstein R, Kurnik D, Almog S, Halkin H. Warfarin and vitamin K intake in the era of pharmacogenetics. Br J Clin Pharmacol 2010;70:164-170. doi: 10.1111/j.1365-2125.2010.03672.x
22. Tanigawara Y. Role of P-glycoprotein in drug disposition. Ther Drug Monit 2000;22:137-140.
23. Wadelius M, Sorlin K, Wallerman O, et al. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J 2004;4:40-48. doi: 10.1038/sj.tpj.6500220
24. Gosland MP, Lum BL, Sikic BI. Reversal by cefoperazone of resistance to etoposide, doxorubicin, and vinblastine in multidrug resistant human sarcoma cells. Cancer Res 1989;49:6901-6905.
25. Rettie AE, Korzekwa KR, Kunze KL, et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin- drug interactions. Chem Res Toxicol 1992; 5:54-59. doi: 10.1021/tx00025a009
26. Lane S, Al-Zubiedi S, Hatch E, et al. The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. Br J Clin Pharmacol 2012;73:66-76. doi: 10.1111/j.1365-2125.2011.04051.x
27. Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis 2011;31:326-343. doi: 10.1007/s11239-011-0561-1
28. Toutain PL, Bousquest-Melou A. Free drug fraction vs free drug concentration: a matter of frequent confusion. J Vet Pharmacol Ther 2002;25: 460-463. doi: 10.1046/j.1365-2885.2002.00442.x
29. Rolan PE. Plasma protein binding displacement interactions-why are they still regarded as clinically important? Br J Clin Pharmac 1994;37: 125-128.
30. Uden P, Svedberg LE, Nordgren A, et al. A study of the interaction of omeprazole and warfarin in anticoagulated patients. Br J Clin Pharmacol 1992;34:509-512.
31. Targownik LE, Bolton JM, Metge CJ, Leung S, Sareen J. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am J Gastroenterol 2009;104:1475-1482. doi: 10.1038/ajg.2009.128
32. Tully PJ, Cardinal T, Bennetts JS, Baker RA. Selective serotonin reuptake inhibitors, venlafaxine and duloxetine are associated with in hospital morbidity but not bleeding or late mortality after coronary artery bypass graft Surgery. Heart Lung Circ 2012;21:206-214. doi: 10.1016/j.hlc.2011.12.002
33. Sarma A, Horne MK. Venlafaxine-induced ecchymoses and impaired platelet aggregation. Eur J Haematol 2006;77:533-537. doi: 10.1111/j.0902-4441.2006.t01-1-EJH2919.x
34. Yavasoglu I, Kadikoylu G, Bolaman Z. Gingival bleeding due to venlafaxine. Ann Pharmacother 2008;42:144-145. doi: 10.1345/aph.1K180
35. Hansen ML, Sorensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010;170:1433-1441. doi: 10.1001/archinternmed.2010.271
36. Lip GYH, Frison L, Halperin JL, Lane DA. Comparative validation of anovel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly,drugs/alcohol concomitantly) score. J Am Coll Cardiol 2011;57: 173-180. doi: 10.1016/j.jacc.2010.09.024
37. Dentali F, Douketis JD, Lim W, Crowther M. Combined aspirin- oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. Arch Intern Med 2007;167:117-124.
38. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002;347:969-974.
39. Gille J, Bernotat J, Böhm S, Behrens P, Löhr JF. Spontaneous hemarthrosis of the knee associated with clopidogrel and aspirin treatment. Z Rheumatol 2003;62:80-81. doi: 10.1007/s00393-003-0420-3
40. Sconce EA, Khan TI, Daly AK, Wynne HA, Kamali F. The impact of simvastatin on warfarin disposition and dose requirements. J Thromb Haemost 2006;4:1422-1424.
41. Westergren T, Johansson P, Molden E. Probable warfarin-simvastatin interaction. Ann Pharmacother 2007;41:1292-1295. doi: 10.1345/aph.1K167
42. Muntane-Relat J, Ourlin JC, Domergue J, Maurel P. Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture. Hepatology 1995;22 (4 pt 1):1143-1153.